Compare LPA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LPA | LUNG |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.0M | 72.2M |
| IPO Year | 2023 | 2020 |
| Metric | LPA | LUNG |
|---|---|---|
| Price | $2.60 | $1.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 10.1K | ★ 645.4K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $83,789,000.00 |
| Revenue This Year | N/A | $6.20 |
| Revenue Next Year | N/A | $21.61 |
| P/E Ratio | $11.25 | ★ N/A |
| Revenue Growth | N/A | ★ 22.01 |
| 52 Week Low | $2.04 | $1.31 |
| 52 Week High | $9.81 | $8.10 |
| Indicator | LPA | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 49.98 | 56.22 |
| Support Level | $2.57 | $1.44 |
| Resistance Level | $2.94 | $1.93 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 72.51 | 52.00 |
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.